Recursion Names Oncology Veteran Vicki Goodman as New Chief Medical Officer — Recursion Pharmaceuticals, Inc.

Event summary

Vicki Goodman, M.D., will become Recursion's Chief Medical Officer effective April 6, 2026, replacing David Mauro, M.D., Ph.D.
Dr. Goodman brings over two decades of experience in oncology drug development, including roles at Mural Oncology, Exelixis, Merck, and Bristol Myers Squibb.
Recursion is advancing its pipeline and preparing for key clinical and regulatory milestones.
Dr. Mauro will transition out of his role after approximately three years at Recursion.

The big picture

Recursion's appointment of Dr. Goodman underscores its focus on translating scientific insights into clinical success, a critical shift as the company moves from discovery to development. Her extensive experience in oncology and regulatory affairs positions Recursion to better compete in a crowded biotech landscape where AI-driven drug discovery is becoming increasingly prevalent. The transition also highlights the strategic importance of leadership continuity in clinical-stage biotech companies as they approach pivotal milestones.

What we're watching

Pipeline Acceleration: How Dr. Goodman's experience in late-stage clinical development will impact Recursion's timeline for key regulatory milestones.
Regulatory Strategy: Whether Dr. Goodman's background as an FDA reviewer will enhance Recursion's ability to navigate complex regulatory pathways.
Execution Risk: The pace at which Recursion can integrate Dr. Goodman's leadership while maintaining continuity in its clinical programs.